C12N 2760/16071
Demonstrated in vivo effect
C12N2760/16071 (Demonstrated in vivo effect) appears on 49 US grants and 101 published applications in this corpus.
Search patents in C12N- Granted patents
- 49
- Published applications
- 101
- Assignees
- 52
- Inventors
- 160
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 2 |
| 2009 | 0 | 2 |
| 2010 | 1 | 2 |
| 2011 | 1 | 5 |
| 2012 | 0 | 3 |
| 2013 | 2 | 1 |
| 2014 | 2 | 7 |
| 2015 | 4 | 7 |
| 2016 | 7 | 17 |
| 2017 | 2 | 8 |
| 2018 | 4 | 9 |
| 2019 | 5 | 7 |
| 2020 | 5 | 2 |
| 2021 | 6 | 4 |
| 2022 | 6 | 7 |
| 2023 | 1 | 4 |
| 2024 | 1 | 7 |
| 2025 | 1 | 1 |
| 2026 | 1 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Multivalent HVT vector vaccine31 Mar 2026US 12,589,147 B2Intervet Inc.
- Influenza B virus replication for vaccine development22 Jul 2025US 12,364,748 B2Wisconsin Alumni Research Foundation (WARF)
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof16 Jul 2024US 12,037,364 B2Sanofi Pasteur Limited
- Vaccines for human papilloma virus and methods for using the same19 Dec 2023US 11,844,830 B2Inovio Pharmaceuticals, Inc.
- Biodegradable polymeric particles encapsulating an active agent, pharmaceutical compositions and uses thereof26 Jul 2022US 11,395,802 B2Altimmune Inc.
- Vaccine compositions and uses thereof9 Apr 2026US 2026/0097112 A1Centivax, Inc.
- Influenza b virus replication for vaccine development12 Feb 2026US 2026/0041756 A1Wisconsin Alumni Research Foundation (WARF)
- Payload delivery system5 Feb 2026US 2026/0034202 A1Imperial College Innovations Limited
- Next generation vaccines comprising antigenic libraries and methods of making and using same8 May 2025US 2025/0144198 A1Duke University
- A vaccine for coronavirus and influenza virus, and method for preparation thereof5 Dec 2024US 2024/0398930 A1Bharat Biotech International Limited
Most cited
By later US patents
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions75US 10,188,748 B2CureVac AG · 2019
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions37US 10,568,972 B2CureVac AG · 2020
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions37US 11,135,312 B2CureVac AG · 2021
- Functional influenza virus like particles (VLPs)35US 8,080,255 B2Novavax, Inc. · 2011
- Treatment of allergic conditions using a composition containing synthetic adjuvant23US 8,343,512 B2Infectious Disease Research Institute · 2013